Editas Medicine, Inc.
Editas Medicine, Inc. (EDIT) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · EDIT · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
14
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Editas Medicine, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
EDIT insider buying and selling by quarter
EDIT insider selling · EDIT insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · EDIT ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
EDIT executive sell shares · EDIT board member insider trading · EDIT insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 3, 2026 | Parison Amy SVP, Chief Financial Officer | Sale | 464 | $1K | Form 4 |
| Jun 3, 2026 | O'Neill Gilmore Neil CEO · Director | Sale | 15,380 | $42K | Form 4 |
| Jun 3, 2026 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 731 | $2K | Form 4 |
| Mar 3, 2026 | O'Neill Gilmore Neil CEO · Director | Sale | 5,394 | $11K | Form 4 |
| Mar 3, 2026 | Parison Amy SVP, Chief Financial Officer | Sale | 474 | $957 | Form 4 |
| Mar 3, 2026 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 749 | $2K | Form 4 |
| Dec 3, 2025 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 713 | $2K | Form 4 |
| Dec 3, 2025 | O'Neill Gilmore Neil CEO · Director | Sale | 5,603 | $12K | Form 4 |
| Dec 3, 2025 | Parison Amy SVP, Chief Financial Officer | Sale | 461 | $993 | Form 4 |
| Sep 3, 2025 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 710 | $2K | Form 4 |
| Sep 3, 2025 | Parison Amy SVP, Chief Financial Officer | Sale | 458 | $1K | Form 4 |
| Sep 3, 2025 | O'Neill Gilmore Neil CEO · Director | Sale | 5,592 | $15K | Form 4 |
| Aug 7, 2025 | Parison Amy SVP, Chief Financial Officer | Sale | 679 | $2K | Form 4 |
| Jul 31, 2025 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 5,121 | $13K | Form 4 |
| Jun 3, 2025 | Parison Amy SVP, Chief Financial Officer | Sale | 446 | $769 | Form 4 |
| Jun 3, 2025 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 726 | $1K | Form 4 |
| Jun 3, 2025 | O'Neill Gilmore Neil CEO · Director | Sale | 15,192 | $26K | Form 4 |
| Mar 4, 2025 | Lucera Erick EVP, CHIEF FINANCIAL OFFICER | Sale | 4,109 | $7K | Form 4 |
| Mar 4, 2025 | O'Neill Gilmore Neil CEO · Director | Sale | 16,632 | $28K | Form 4 |
| Mar 4, 2025 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 2,891 | $5K | Form 4 |
| Dec 3, 2024 | O'Neill Gilmore Neil CEO · Director | Sale | 1,618 | $3K | Form 4 |
| Dec 3, 2024 | Mei Baisong EVP, CHIEF MEDICAL OFFICER | Sale | 541 | $1K | Form 4 |
| Sep 4, 2024 | Mei Baisong EVP, CHIEF MEDICAL OFFICER | Sale | 518 | $2K | Form 4 |
| Sep 4, 2024 | O'Neill Gilmore Neil CEO · Director | Sale | 1,555 | $5K | Form 4 |
| Jul 25, 2024 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale | 11,886 | $64K | Form 4 |
Parison Amy
SVP, Chief Financial Officer
Date
Jun 3
Shares
464
Price
$2.70
Value
$1K
O'Neill Gilmore Neil
CEO · Director
Date
Jun 3
Shares
15,380
Price
$2.70
Value
$42K
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Date
Jun 3
Shares
731
Price
$2.70
Value
$2K
Parison Amy
SVP, Chief Financial Officer
Date
Mar 3
Shares
474
Price
$2.02
Value
$957
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Date
Mar 3
Shares
749
Price
$2.02
Value
$2K
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Date
Dec 3
Shares
713
Price
$2.15
Value
$2K
Parison Amy
SVP, Chief Financial Officer
Date
Dec 3
Shares
461
Price
$2.15
Value
$993
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Date
Sep 3
Shares
710
Price
$2.60
Value
$2K
Parison Amy
SVP, Chief Financial Officer
Date
Sep 3
Shares
458
Price
$2.60
Value
$1K
Parison Amy
SVP, Chief Financial Officer
Date
Aug 7
Shares
679
Price
$2.58
Value
$2K
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Date
Jul 31
Shares
5,121
Price
$2.49
Value
$13K
Parison Amy
SVP, Chief Financial Officer
Date
Jun 3
Shares
446
Price
$1.72
Value
$769
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Date
Jun 3
Shares
726
Price
$1.72
Value
$1K
O'Neill Gilmore Neil
CEO · Director
Date
Jun 3
Shares
15,192
Price
$1.72
Value
$26K
Lucera Erick
EVP, CHIEF FINANCIAL OFFICER
Date
Mar 4
Shares
4,109
Price
$1.71
Value
$7K
O'Neill Gilmore Neil
CEO · Director
Date
Mar 4
Shares
16,632
Price
$1.71
Value
$28K
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Date
Mar 4
Shares
2,891
Price
$1.71
Value
$5K
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Date
Jul 25
Shares
11,886
Price
$5.42
Value
$64K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About EDIT insider trading
EDIT insider trades
Editas Medicine, Inc. (EDIT) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Parison Amy (SVP, Chief Financial Officer), Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER), O'Neill Gilmore Neil (CEO · Director). Over the past 12 months, 3 insiders have filed transactions with the SEC. EDIT insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Editas Medicine, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
EDIT insider trading · 5 questionsThe insiders of Editas Medicine, Inc. (EDIT) include executives and directors such as Parison Amy (SVP, Chief Financial Officer), Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER), O'Neill Gilmore Neil (CEO · Director), among others. Over the past 12 months, 3 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026